fda compounding glp-1 warning letters september 2025 U.S. sends drug advertising to Lilly, Novo, Hims FDA Drug Recalls and Warnings:

11.5 Who Should Be Monitored More Closely Monitoring becomes more relevant when: Weight loss exceeds 1520% Appetite suppression leads to persistent under-eating GI symptoms persist Pre-existing marginal status exists Combination therapy (e.g., metformin) is used Older adults are treated Oversight should be proportional to risk

caution advised

[70] showed that adherence to the Mediterranean diet was lower in children with ADHD

Reporting suspected adverse reactions helps the MHRA monitor the ongoing safety of medicines used in the UK

[PMID: 4846313] PubMed record related to this compound for laboratory literature review